Week Ahead: IRSF (NGNE Interim Update; TSHA REVEAL Part A Encore); ESMO GI

Research evidence excerpt

Week Ahead: IRSF (NGNE Interim Update; TSHA REVEAL Part A Encore); ESMO GI

USA | Biotechnology EquityJuneResearch28, 2026

Week Ahead: IRSF (NGNE Interim Update; TSHA

REVEAL Part A Encore); ESMO GI

We're attending IRSF this wk (June 29 to July 1), where TSHA's comp NGNE will

show updated ph.I/II data June 29/30 (pot'ly poster June 29; oral pres June 30

@9:40AM ET), w/ pot'l readthrough to TSHA (+10%/-20%). TSHA will show an

encore presentation w/ REVEAL Part A update June 30. We're hosting a dinner

June 29 w/ KOL Dr. David Lieberman of Boston's Children's Hospital (COE) to

discuss TSHA vs NGNE. ESMO GI Cancer (July 1-July 4) is also this wk.

Upcoming medical confs

European Association of Neurology (June 27-30): abstracts post June 26 @12:30PM ET•

International Conference on Children's Bone Health (June 27-30):•

TYRA-related: BBIO presented an LBA today w/ ph.III PROPEL 3 w/ Infigratinib in •

achondroplasia @ICCBH (June 27-30)

International Rett Syndrome Foundation (June 29–July 1): full program w/ abstracts here•

TSHA (oral presentation): Safety and Efficacy Results from the REVEAL Part A Phase •

1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts. June 30 10:00-10:20

AM ET.

TSHA (co-sponsored symposium): Establishing the Rett Syndrome Developmental •

Milestone Assessment (RS-DMA) as a Primary Endpoint for Interventional Studies.

July 1 @9:10AM ET.

TSHA (poster #59) Safety and Efficacy Results from the REVEAL Part A Phase 1/2 •

Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts. June 30 @4:40 PM ET.

TSHA (poster #39): The Developmental Plateau in Rett Syndrome: New Insights •

from the Natural History Study Inform Novel Interventional Study Designs. June 29

@4:10PM ET.

TSHA (poster #7): Establishing the Rett Syndrome Developmental Milestone •